Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzafatide pevedotin (formerly 5528), a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; zelenectide pevedotin (formerly BT8009), a BDC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts, USA. For more information, visit bicycletherapeutics.com
Culture is key and all Bicycle employees actively embrace and role model our company values:
- We are Adventurous. We believe it’s the way to deliver extraordinary results for our patients.
- We are Dedicated to our Mission. You can’t change the world if you don’t have determination.
- We are One Team. We only succeed when we work together.
Your mission is to apply your skills in radiobiology to support the preclinical development of our innovative Bicycle® Radio-Conjugates (BRCs™). You will conduct key in vitro and in vivo experiments, generating the high-quality data needed to understand the efficacy and mechanism of action of our next-generation cancer therapies.
Working location: This is a hybrid position with the majority of attendance being at our office in London (up to 4 days per week), in the vicinity of Kings Cross, with an ongoing requirement to visit the Cambridge Office up to 2 days per month.
YOUR RESPONSIBILITIES
Scientific & Project Execution
- Conduct in vitro and in vivo studies to evaluate the efficacy, mechanism of action, and radiobiological effects of our BRCs, following established study designs.
- Perform a range of assays to probe DNA damage response, cell cycle effects, and mechanisms of cell death.
- Characterize the effects of targeted radionuclide therapy on both tumour cells and the tumour microenvironment.
- Support radiobiology research conducted through CROs and academic collaborations by assisting with material transfer and data organization.
Data Analysis & Communication
- Diligently document all experimental work and clearly communicate results to your manager and project team.
- Contribute to the identification of potential pharmacodynamic biomarkers through careful experimental work.
- Contribute to scientific publications and conference presentations through your data generation and analysis.
WHO ARE YOU: SKILLS & COMPETENCIES
Knowledge & Expertise
- Core Expertise: You apply solid scientific knowledge to plan and conduct radiobiology experiments with growing independence.
- Data / Insight: You interpret experimental results, identifying trends and drawing clear conclusions from your data.
- Knowledge Sharing: You share your expertise and observations with peers to build the team's collective capability.
Job Complexity
- Task / Project Delivery: You deliver work of moderate complexity independently, taking ownership of your assigned experiments and ensuring reliable results.
- Problem-Solving: You adapt established methods to address new scientific challenges and troubleshoot issues in your experiments.
- Strategic Impact: You contribute key insights and reliable data that support team decision-making on a project level.
Independence
- Autonomy: You work independently on defined projects with limited oversight on routine work.
- Decision-Making: You select appropriate methods to achieve experimental objectives and deliver high-quality data.
- Leadership / Mentorship: You provide guidance to less experienced colleagues, sharing your knowledge of specific assays and techniques.
Values & Behaviours
One Team
- Collaboration: You work constructively within and across teams to ensure your work is aligned with project goals.
- Inclusive Leadership: You encourage input from colleagues with different perspectives to enhance the quality of your work.
- Mentorship / Support: You actively share knowledge and offer support to your peers.
Adventurous
- Innovation: You suggest new approaches to experiments or improvements to existing assays.
- Risk-Taking: You learn from experimenting with novel methods and are willing to try new techniques.
- Change Leadership: You support the team's transition to new processes or technologies.
Dedicated to our Mission
- Accountability: You take ownership for the quality and reliability of your experimental results.
- Resilience: You remain focused and determined when experiments do not go as planned.
- Inspiration: You demonstrate commitment by linking your daily work to our mission of helping patients.
- A strong educational background in radiobiology, cancer biology, or a related field.
- Hands-on experience with a range of in vitro radiobiology techniques (e.g., clonogenic survival, DNA damage assays, cell cycle analysis).
- A solid understanding of the biological effects of ionizing radiation.
- Experience with targeted radiotherapeutics or preclinical imaging would be an advantage.
- Hands-on experience with a range of in vivo techniques, such as nuclear imaging and biodistribution studies, is highly desirable
- A collaborative mindset with strong organizational and communication skills.
- State-of-the-art campus environment with on campus restaurant and Montessori nursery
- Flexible working environment
- Competitive reward including annual company bonus
- Employee recognition schemes
- 28 days annual leave in addition to bank holidays + option to buy up to 5 additional days annually
- Employer contribution to pension (employee does not have to contribute)
- Life assurance cover 4x basic salary
- Private Medical Insurance, including optical and dental cover
- Enhanced parental leave policies
- Group income protection
- Employee assistance program
- Health Cash Plan
- Access to company subsidized gym membership
- Eligibility for an option grant to subscribe to shares in Bicycle Therapeutics plc.
- Cycle to work scheme
Bicycle Therapeutics is committed to building a diverse workforce that is representative of the communities we serve. We recognize that diverse and inclusive teams build a stronger and more innovative company. Therefore, all qualified applicants will be considered for employment, and we do not discriminate on the basis of race, religion, colour, gender, sexual orientation, age, disability status, marital status, or veteran status.
Bicycle Therapeutics is committed to building a diverse workforce that is representative of the communities we serve. We recognize that diverse and inclusive teams build a stronger and more innovative company. Therefore, all qualified applicants will be considered for employment, and we do not discriminate on the basis of race, religion, colour, gender, sexual orientation, age, disability status, marital status, or veteran status.
Skills Required
- Strong educational background in radiobiology, cancer biology, or a related field
- Hands-on experience with in vitro radiobiology techniques (e.g., clonogenic survival, DNA damage assays, cell cycle analysis)
- Solid understanding of the biological effects of ionizing radiation
- Experience with targeted radiotherapeutics or preclinical imaging
- Hands-on experience with in vivo techniques such as nuclear imaging and biodistribution studies
- Strong organizational and communication skills and ability to document experimental work rigorously
What We Do
We are Bicycle Therapeutics, a clinical-stage biopharmaceutical company. We didn’t wait for the next advance against cancer. We created it. Based on groundbreaking work conceived in the laboratory of Sir Greg Winter with the help of Professor Christian Heinis, we are pioneering the development of bicyclic peptides, or Bicycles® – a novel class of versatile, chemically synthesized medicines. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles represent a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed to date. Bicycles can be used as Bicycle conjugates to deliver toxin payloads and to precisely target local immune activation within tumors and as Bicycle T-cell modulators, which activate cytotoxic T-cells while circumventing the limitations of antibody and biologic therapies and better enabling combination therapy. Our lead product candidate, BT1718, is a Bicycle toxin conjugate currently being investigated in a Phase I/IIa open label dose escalation and expansion clinical trial sponsored by Cancer Research UK. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14, which is highly expressed in many solid tumors. Our strategic collaborations are based on the ability of Bicycles to address a wide variety of targets. Through collaborations with AstraZeneca, Oxurion, Innovate UK and the Dementia Discovery Fund, we work with companies that have deep therapeutic expertise outside of oncology to enable us to more efficiently develop novel medicines for patients.
